NCT02097810View on ClinicalTrials.gov

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2014

Primary Completion Date

June 2, 2020

Study Completion Date

June 2, 2020

Conditions

Locally Advanced Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

Entrectinib

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Georgetown University Medical Center, Washington D.C.

34232

Florida Cancer Specialists - Sarasota, Sarasota

37203

Tennessee Oncology, Nashville

77030

University of Texas M.D. Anderson Cancer Center, Houston

80045

University Of Colorado, Aurora

92868

UC Irvine Medical Center, Orange

94158

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco

02114

Massachusetts General Hospital, Boston

06531

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02097810 - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. | Biotech Hunter | Biotech Hunter